Original Research J Clin Psychiatry September 2025

Aripiprazole or Bupropion Augmentation Versus Switching to Bupropion in Treatment-Resistant Depression: A Risk-Benefit Analysis

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Patients with treatment-resistant depression often face a tradeoff between greater symptom benefit and meaningful long-term harms when clinicians choose between switching to bupropion, adding bupropion, or augmenting with aripiprazole. This analysis matters because it integrates remission benefits with falls, weight gain, and tardive dyskinesia to show how age and baseline BMI can change which option offers the best overall health benefit. FAQ Which treatment had the best overall risk-benefit balance for treatment-resistant depression in this analysis? 12 questions
Key Takeaways Baseline BMI materially changed the ranking of aripiprazole: A-ARI was preferred over S-BUP only in patients with nonelevated weight, while S-BUP was preferred over A-ARI in patients who were overweight at baseline. 6 takeaways Clinical Guide How should clinicians choose between bupropion augmentation, aripiprazole augmentation, and switching to bupropion for treatment-resistant depression using age and baseline BMI? 8 steps Clinical Guide When should clinicians avoid aripiprazole augmentation in treatment-resistant depression because harms outweigh benefits? 7 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Live Webinar
and Q&A With
Dr Deligiannidis

JULY 16 · REGISTER NOW
Webinar ad featuring Dr. Kristina M. Deligiannidis on PPD treatment options

Subscribe to read
more articles

Subscribe